Business
Adult-Use Cannabis Sales Expected To Begin in Connecticut in 2023
Although cannabis sales were originally expected to hit in Connecticut at the end of 2022, new progress on license applications now points to 2023.
The Connecticut Department of Consumer Protection (DCP) recently informed three medical cannabis producers that they will receive an expanded producer license, which will allow them to work with both medical cannabis and adult-use cannabis products.
DCP Commissioner Michelle H. Seagull said in a press release that this is one of the final steps toward a regulatory market sometime next year. “The Department’s priority is to have a safe, well-regulated marketplace for consumers,” said Seagull. “I am grateful to the Drug Control and Legal teams at DCP who have worked—and continue to work—tirelessly, since the passage of the law, toward a safe and successful market opening.”
Connecticut law states that sales can’t begin until 250,000 square feet of growing and manufacturing space is approved for adult-use. In a press release from the DCP, the department said that cannabis sales can’t proceed until the state’s four medical cannabis producers and cultivators have been approved. Currently, this includes Advanced Grow Labs LLC, Connecticut Pharmaceutical Solutions LLC, and Curaleaf LLC. One more application from Theraplant was received on Nov. 10, and the DCP is reviewing that application for license conversion.
Additionally, seven medical cannabis dispensaries also received confirmation that they’ve met the criteria for conversion to a hybrid cannabis license, however these do not contribute to the minimum 250,000 square footage requirement that will allow sales to begin.
Since Connecticut Gov. Ned Lamont signed a bill to legalize recreational cannabis in June 2021, the DCP has continually grown its department to meet the anticipated demands of a growing industry. The Drug Control and Legal Divisions department has increased to 38 people, and numerous business licenses have been approved. To date, this includes six micro-cultivation licenses, nine provisional cultivator licenses, and 27 retail licenses.
Just one month after Lamont signed the bill, Connecticut officials launched a cannabis education and information website to clear up questions that residents may have. In September, there had already been an expectation that sales could be delayed. “We’ve been suggesting that there will likely be sales by the end of 2022, and we’re still aspiring for that. Obviously, we have to see how things play out in the next few months,” Seagull said in September 2021. “It’s really important to us that we preserve the medical marketplace that currently does exist. It’s important to us that that market, which is working well and helping a lot of people, doesn’t get swallowed up.”
Earlier this year in May, more than 15,000 dispensary applications were submitted with anticipation of sales beginning in Connecticut soon. Additionally Gov. Lamont signed legislation earlier this year in May to address the ongoing practice of cannabis gifting that lies in a grey area of sales.
Most recently in September, the state launched a new educational campaign “to promote responsible cannabis use by adults.” “Protecting public health and safety includes providing people with the tools and knowledge to make informed decisions to keep their families safe,” said Lamont about the campaign. “We’re working to educate the public about the steps they can take to protect themselves and their families from accidental ingestion and over-consumption. We encourage adults who choose to use these products to do so responsibly.”
According to the 2022 MJBiz Factbook, Connecticut could collect up to $250 million in the first full year of sales, and $750 million by the fourth year.
Connecticut is one of New York’s eastern neighbors, and news of Connecticut’s progress arrived just one day after the New York Office of Cannabis Management announced its first round of license approvals. This included 28 “justice-involved individuals” and eight non-profit organizations. According to New York Gov. Kathy Hochul, the state plans to open its first 20 dispensaries by the end of 2022.
Source: https://hightimes.com/news/adult-use-cannabis-sales-expected-to-begin-in-connecticut-in-2023/
Business
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Business
Marijuana companies suing US attorney general in federal prohibition challenge
Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.
According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”
Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.
The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”
The companies want the case to go before the U.S. Supreme Court.
They hired prominent law firm Boies Schiller Flexner to represent them.
The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.
Similar challenges to the federal Controlled Substances Act (CSA) have failed.
One such challenge led to a landmark Supreme Court decision in 2005.
In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.
In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.
Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.
“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.
“Moreover, the facts on which those precedents are based are no longer true.”
Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”
While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.
“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”
Business
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
-
Business1 year ago
Pot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business1 year ago
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business1 year ago
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year ago
Washington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business1 year ago
Marijuana companies suing US attorney general in federal prohibition challenge
-
Business1 year ago
Legal Marijuana Handed A Nothing Burger From NY State
-
Business1 year ago
Can Cannabis Help Seasonal Depression
-
Blogs1 year ago
Cannabis Art Is Flourishing On Etsy